Although IL-1 was first characterised as a haematopoietic growth factor, it is now known to have biological effects in many different cell types. Two different peptides without marked difference in their biological activity, but with only 26% homology at the protein level, each of a molecular mass of 17 kDa, are termed IL-la and IL-1p. Binding studies with lymphocytes revealed high-(KD 5 x 10-11 M) and low-(KD 5 x 10-9M) affinity binding sites (Mizel et al., 1987; McMahan et al., 1991) . Two different receptors of 80 kDa (type I) and 68 kDa (type II) have been detected by protein analysis, the former mainly, but not exclusively, on T cells and fibroblasts and the latter on B cells. cDNAs of both receptors have been cloned and expressed (Solari, 1990; Ruhl et al., 1992) . High-and low-affinity binding sites for both IL-lo and IL-1p may be co-located on one or both receptors (Solari, 1990; Slack et al., 1993) . Both IL-1 receptors contain an immunoglobulin-like domain which binds IL-1, but the overall homology of this region in type I and type II receptors is only 28% (McMahan et al., 1991; Ruhl et al., 1992) . It has been reported that signal transduction is exclusively mediated through receptor type I, which has an intracellular domain of 217 amino acids (Sims et al., 1993) . Despite lacking homology to any known protein, this intracellular domain is sufficiently long to encode for yet unidentified enzymatic function. In contrast, IL-1 receptor type II has a short intracellular domain of only 29 amino acids and might trap IL-1 without subsequent signal transduction, thus regulating IL-i-induced biological responses (McMahan et al., 1991; Colotta et al., 1993) .
While IL-I is a known growth factor for T and B cells, its potential significance for tumour cell proliferation is less clear. Some tumours appear to be stimulated, but growth of others is inhibited in vitro (Michiel and Oppenheim, 1992) . Binding of tumour cells to endothelial cells in vitro and to blood vessel endothelium in vivo is enhanced under the influence of IL-1 (Giavazzi et al., 1990; Lauri et al., 1990 
Ligand-receptor cross-linking and immunoprecipitation
Cells (confluency 90%) were incubated with 5 ng ml' IL-lp for 3 h. at 4°C and washed four times with ice-cold PBS. Cross-linking was performed with DSS (1 mg ml-') in PBS for 1 h at 4°C. Cells were washed twice with PBS, harvested wtih 20 mM EDTA in PBS and lysed with 1% Triton X-100 in PBS. Cell debris was removed by centrifugation. Lysates were diluted to a concentration of 0.5 mg ml-' protein with NET buffer (50 mM Tris-HCI pH 8.0, 150 mM sodium chloride, 0.1% Nonidet-P40, 1 mM EDTA, 0.25% gelatin) and incubated with antibodies against IL-l at a concentration of 10 fg ml-' for 1 h at 4C. Protein G-cellulose was added and the incubation was continued for 1 h at 4°C. Unbound proteins were removed by five washes with NET buffer. SDS-polyacrylamide gel loading buffer (25 mM Tris-HCI pH 6.8, 2% SDS, 1% 2-mercaptoethanol, 10% glycerin, 0.25% bromophenol blue) was added to the final protein G-cellulose pellet and samples were boiled for 5 min and cooled on ice. After electrophoresis on 10% acrylamide gels, proteins were blotted onto nitrocellulose filters (Laemmli, 1970) . Filters were subsequently incubated with the antibody against IL-lp and a horseradish peroxidase-coupled anti-mouse antibody and stained with diaminobenzidine.
For direct immunoprecipitations of the receptor, cell lysates were incubated with antibodies against IL-1 receptor type I or II without prior cross-linking. In this case, Western blots were treated with anti-receptor antibodies.
Results
Freshly explanted human tumour cells were cloned in soft agar with or without IL-la or IL-ip (0.1-l00ngmlV') to investigate the influence of IL-l on the clonogenic growth of human tumour cells (Buick and Salmon, 1980; Salmon and Salmon, 1980) . Cell viability and-cloning efficiency varied depending on the individual tumour examined. All results are expressed as colony survival relative to untreated controls. Endotoxin controls were included when preparations of IL-1-containing endotoxin were used. A tumour specimen was regarded as being stimulated if the number of colonies increased to more than 1.5 times control and as inhibited if the number of colonies decreased to less than 0.5 times control (Clark and Von Hoff, 1983) .
Eighteen per cent of renal carcinomas were stimulated by IL-la and thus were the most sensitive subgroup (Table I) . Data obtained with freshly explanted human tumour cells were reproduced with established cell lines. Care was taken to keep the passage number as low as possible (between 15 and 50) and relatively constant for each cell line. Of the four cell lines used, two were from primary tumours (Caki-2 and A498), one was from a skin metastasis of a renal carcinoma (Caki-l) and one from a pleural effusion of a patient with widely metastatic renal carcinoma (ACHN). All cell lines were tested for endogenous production of IL-la and IL-lp and were found not to release either cytokine into the medium (data not shown).
Clonogenic growth of tumour cell lines from primary cancers was stimulated in a concentration-dependent manner by IL-la and IL-1p. With Caki-2 cells, stimulation was observed in tissue culture medium containing 10% FCS and reached 3.4 times control at 10 ng ml' IL-Ip and 2.5 times control at 100 ng IL-la (Figure 2a) . In contrast, A-498 cells were only stimulated after serum deprivation (1% FCS) with maximal effect of 2.0 times control at 100 ng ml-' IL-Iac and 2.4 times control at 100 ng ml1 IL-lp (Figure 2b Specimens were considered to be stimulated if the average colony formation was > 1.5 times control and to be inhibited if the average colony fonnation was < 0.5 times control (Clark and Von Hoff, 1983 ). Figure   3c ). Similar results were obtained in a monolayer growth experiment. After 72 h of incubation, cell numbers were 0.5 times control after incubation with 0.1 or 1O ng ml-' IL-1 ( Figure 3d (Figure Sb) . Preliminary data from Scatchard analyses of IL-1 radioreceptor assays with and without IL-la preincubation indicate that reduced IL-la binding after IL-la preincubation is due to reduced affinity of the high-affinity receptors rather than to reduced receptor numbers (data not shown). sitivity of the available methods is insufficient to identify these weakly expressed molecules. (Paciotti and Tamarkin, 1988) . The human ovarian carcinoma cell line has been reported to express 7800 sites per cell with a KD of 55 pM (Tsai and Gaffney, 1987) . Lower receptor numbers have been found on NIM-1 human thyroid carcinoma cells (664 molecules per cell, KD 110 pM) as well as in MDA-MB-415 breast cancer cells (700 per cell, KD 880 pM) (Gaffney et al., 1988; Zeki et al., 1993 al., 1992) . However, Scatchard analyses clearly indicate that reduced binding to A498 cells is not due to reduced receptor number, but rather to reduced receptor affinity. In this context it may be interesting to note that receptor number might have little or no influence on the extent of the biological response, since a receptor occupancy of 1-100 molecules per cell has been reported to be sufficient for efficient signal transduction (Dower et al., 1985) . However, reduced affinity of highaffinity receptors may well weaken the biological signal, particularly at low concentrations of ligand.
While 250 high-affinity receptors on A-498 cells are sufficient for effective signal transduction, a far lower receptor number, which is too low for identification by radioreceptor assays, may account for IL-i-induced growth stimulation of Caki-2 cells.
From our experiments, we cannot exclude the possibility that Caki-I and ACHN cells also express a small number of cell-surface receptors. However, if this is the case, binding of IL-1 to its receptor does not change the growth behaviour of these cells.
Early reports have postulated that both type I and type II IL-1 receptors are functional in ligand binding and capable of signal transduction. However, recent reports support the notion that only receptor type I can mediate IL-1-induced biological effects, at least in lymphocytes (Sims et al., 1993) . While the intracellular domain of this molecule with 217 amino acids is large enough for a yet unidentified enzymatic function, the intracellular domain of receptor type II is too short. Binding of IL-1 to receptor type II may reduce the effective IL-1 concentration and thus may have a regulatory function with regard to biological effects (Colotta et al., 1993) . In Caki-2 and A-498 cells, IL-i-induced stimulation of clonogenic growth was prevented by antibodies to receptor type I but not to receptor type II. This indicates that IL-1 signal transduction in these cells is also conferred via this receptor type. Similarly, binding of IL-1 to A-498 cells was inhibited by 50% by antibodies to receptor type I at the concentrations of antibody used. We therefore conclude that renal cancer cells mainly express IL-1 receptor type I. Inhibition of IL-1 binding by 25% by antibody to receptor type II may be explained by a lack of specificity of the antibodies used.
In confirmation of cell biological data, a single band of about 100 kDa was immunoprecipitated by antibodies to IL-l( after cross-linking of IL-lx to A-498 cells. The size of this band corresponds to IL-I receptor type I (80 kDa) crosslinked to . No band of minor size which might represent IL-I receptor type 11 (60 kDa) was identified. We therefore hypothesise that binding of IL-1 to renal carcinoma cells occurs via IL-1 receptor type I and that this receptor is also responsible for signal transduction. Similar results have been obtained with MCF-7 cells, indicating a general role for receptor type I in IL-1 signal transduction not only in lymphocytes but also in cancer cells (Paciotti and Tamarkin, 1988) .
In summary, our data indicate that IL-1 can modulate growth of human renal cancer cells and that this effect is conferred by IL-1 receptor type I.
Abbrevations DSS, disuccinimidylsuberate; HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid; SDS, sodium docecyl sulphate; FCS, fetal calf serum; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay.
